About Us

OrsoBio is on a mission to redefine the treatment of metabolic diseases by addressing their root cause.

OrsoBio is a clinical-stage biopharmaceutical company developing first-in-class therapies to address the underlying causes of organ dysfunction in patients with severe metabolic disorders. Our dedicated, highly skilled, and cohesive team of physicians and scientists bring decades of clinical and drug development experience, from academia and industry, that serves as the foundation of our company. 

Our Leadership

Chief Medical Officer and Head of Development

Scientific Advisors

Scientific Advisor

Scientific Advisor

Scientific Advisor

Board of Directors

Chairman of the Board

Co-Founder and Chief Business and Financial Officer

Who We Work With

Our Investors

Our Partners

Headshot of CEO of biopharmaceutical company OrsoBio - Mani Subramanian

G. Mani Subramanian, MD, PhD​

CEO and Founder​

Dr. Subramanian has spent more than 20 years advancing first-in-class therapies to approval. He was previously Senior Vice President and Therapeutic Area Head for Liver Diseases at Gilead Sciences where he oversaw approval of multiple therapies for viral hepatitis (Sovaldi®, Harvoni®, Epclusa®, Vosevi®, Vemlidy®) and a portfolio of compounds in NASH and other liver diseases. Previously, he was at Human Genome Sciences where he developed albumin-fusion proteins and monoclonal antibodies. He started his biotechnology career at Celera Genomics where he made major contributions to the sequencing and annotation of the human and mouse genomes.

Dr. Subramanian received his Internal Medicine training at University Hospitals of Cleveland (CWRU) and Infectious Diseases fellowship at NIAID, NIH. He holds a PhD degree from University of Michigan and MD from Armed Forces Medical College, India.

Headshot of Rob Myers, Chief Medical Officer and Head of Development, Biopharmaceutical company OrsoBio

Rob Myers, MD

Chief Medical Officer and Head of Development​

Dr. Myers is a hepatologist with over 20 years’ experience in academia and the biopharmaceutical industry. He was previously Vice President at Gilead Sciences, where he oversaw clinical development in liver fibrosis (NASH, cholestatic and alcoholic liver disease) and GI inflammation, and Associate Professor of Medicine at the University of Calgary. Dr. Myers has published over 200 peer-reviewed scientific manuscripts and was awarded a Queen Elizabeth II Diamond Jubilee Medal for his contributions to research and patient care in liver disease. 

Dr. Myers received his MD and Internal Medicine training at Western University, Gastroenterology fellowship at the University of Calgary, and Hepatology fellowship at the Université de Paris VI, and holds a master’s degree in Epidemiology from the University of Calgary.

Headshot of Gerald Shulman, Scientific Advisor, Biopharmaceutical company OrsoBio

Gerald Shulman, MD, PhD

Scientific Advisor

Dr. Shulman is the George R. Cowgill Professor of Medicine and Cellular & Molecular Physiology at Yale University. He is also Co-Director of the Yale Diabetes Research Center and was an Investigator of the Howard Hughes Medical Institute for 21 years. Dr. Shulman has pioneered the non-invasive assessment of glucose and fat metabolism in humans and rodent models, and his discoveries have led to paradigm shifts in our understanding of diabetes and molecular mechanisms of insulin resistance. 

Dr. Shulman is the recipient of the Banting Medal for Lifetime Scientific Achievement from the American Diabetes Association. He has been elected to the American Society for Clinical Investigation, the Association of American Physicians, the National Academy of Medicine, and the National Academy of Sciences.

Headshot of Johan Awerx, Scientific Advisor, biopharmaceutical company OrsoBio

Johan Auwerx, MD, PhD

Scientific Advisor

Dr. Auwerx is Professor at the École Polytechnique Fédérale de Lausanne (EFPL), Switzerland, where he heads the Laboratory of Integrative Systems Biology. Dr. Auwerx uses molecular physiology and systems genetics approaches to understand mitochondrial function and metabolism in health, aging, and disease. His research has spurred the development of new drugs for the treatment of metabolic, cardiovascular, renal, and neuromuscular diseases, including PPAR agonists, urolithin A, PARP inhibitors, and other NAD+ enhancers.

Dr. Auwerx was elected as a member of EMBO in 2003 and founded multiple biotech companies including Mitobridge, Carex, and PhytoDia.

Headshot of Takanori Takebe, Scientific Advisor, Biopharmaceutical company OrsoBio

Takanori Takebe, MD, PhD

Scientific Advisor

Dr. Takebe is Chair of Organoid Medicine, Division of Gastroenterology, Hepatology and Nutrition Division of Developmental Biology Center for Stem Cell and Organoid Medicine (CuSTOM) Cincinnati Children’s Hospital Medical Center. Dr. Takebe is a Principal Investigator at the Takeda-CiRA joint program and full professor at Tokyo Medical and Dental University. He integrates cutting-edge stem cell biology and organoid technology to facilitate research of human biology and disease. 

Dr. Takebe is on the Board of Directors for the International Society for Stem Cell Research (ISSCR) and is an elected member of American Society of Clinical Investigation (ASCI) and recipient of the Robertson Investigator Award from the New-York Stem Cell Foundation.

Headshot for Srini Akkaraju, Board of Directors, Biopharmaceutical company OrsoBio

Srini Akkaraju, MD, PhD

Board of Directors

Dr. Srinivas Akkaraju is the Founder and Managing General Partner at Samsara BioCapital. Previously, from April 2013 to February 2016, he served as a General Partner of Sofinnova Ventures. From January 2009 until April 2013, he served as Managing Director of New Leaf Venture Partners. Previously, he served as a Managing Director at Panorama Capital, LLC, a private equity firm. Prior to co-founding Panorama Capital, Dr. Akkaraju was with J.P. Morgan Partners, which he joined in 2001 and of which he became a Partner in 2005. From October 1998 to April 2001, he was in Business and Corporate Development at Genentech, Inc. (now a wholly owned member of The Roche Group), a biotechnology company, most recently as Senior Manager.

Prior to joining Genentech, Dr. Akkaraju was a graduate student at Stanford University, where he received his M.D. and a Ph.D. in Immunology. He received his undergraduate degrees in Biochemistry and Computer Science from Rice University. Dr. Akkaraju also serves as a director of Intercept Pharmaceuticals and Syros Pharmaceuticals.  Previously, he served as a director on the boards of Seattle Genetics, Principia Biopharma, Aravive, Inc., Barrier Therapeutics, Eyetech Pharmaceuticals, ZS Pharma, Synageva Biopharma Corp. and Amarin Corporation.

Edd Fleming, MD

Director

Dr. Edd Fleming joined OrsoBio’s Board of Directors in October 2023. Edd is the Executive Vice President of Enavate Sciences where he works closely to invest in and build therapeutic companies. In 2022, Edd retired as Senior Partner at McKinsey & Company where he worked extensively with both large and small biopharmaceutical companies on their priority strategic and operational priorities. He was the global leader of McKinsey’s R&D practice where he was responsible for its client service and knowledge development on R&D topics. Edd earned his B.A. in Chemistry from Harvard University, his M.D. from Vanderbilt University, and completed internal medicine training at Johns Hopkins Hospital and subspecialty training in pulmonary and critical care medicine at the University of California, San Francisco. Edd serves on the Boards of CRISPR Therapeutics, Komodo Health, Upstream Bio and the Board of Visitors for Vanderbilt’s School of Basic Sciences.
Headshot for Corey Friedland, Board of Directors, Biopharmaceutical company OrsoBio

Cory Freedland, PhD

Director

Cory joined Samsara in 2017. Prior to Samsara, Cory was a Principal at Sofinnova Ventures where he focused on biopharmaceutical investments. Cory played a central role in Sofinnova’s investments in BioClin Therapeutics, Civitas (acquired by Acorda), NextCure, NuCana Biomed (NCNA), Principia Biopharma, Spark Therapeutics (ONCE), Ziarco (acquired by Novartis), and ZS Pharma (ZSPH; acquired by AstraZeneca). Prior to Sofinnova, Cory was a Principal at Novo A/S.

Before his transition to healthcare investing, he was a Vice President in the healthcare investment banking practice at Morgan Stanley where he advised on over $12 billion of strategic and financing transactions in the biopharmaceutical and life science tools/diagnostics sectors. Prior to transitioning to life sciences finance, Cory worked as a research scientist for Roche focusing on preclinical drug discovery and novel target identification for psychiatric and neurodegenerative diseases.

He received his PhD in Pharmacology from Wake Forest University School of Medicine and his MBA from the Kellogg School of Management. Cory holds a BA in Psychology and Religious Studies from Connecticut College.

Headshot of Muzammil Mansuri, Board of Directors, biopharmaceutical company OrsoBio

Muzammil Mansuri, PhD

Board of Directors

Muz Mansuri joined F-Prime Capital in January 2020 as a Venture Partner and is based in the Boston office. Muz works with various F-Prime team members to evaluate therapeutic and digital investment and company creation opportunities. Muz has more than 35 years of experience in various R&D roles as a senior executive within the global biopharmaceutical industry.

Prior to joining F-Prime, Muz was a member of the Executive Committee at Sanofi, as Executive Vice President, Strategy, Business Development, and Licensing. Among other responsibilities, Muz headed the Strategy, Business Development, Alliance Management and the Venture Group for Sanofi. Before this, he was at Gilead Sciences as Senior Vice President, Research and Development Strategy and Business Development. In that capacity he led the R&D Strategy, Business Development, and M&A activities for the company. Muz has served as Chief Executive Officer of several biotech companies and as a General Partner at Flagship Ventures (now Flagship Pioneering). He began his career in the pharmaceutical industry as a bench medicinal chemist with Bristol Myers.

Muz received his B.Sc. and Ph.D. in Chemistry from the University College London. He conducted postdoctoral research at UCLA and Columbia University.

Matthew Young

Director

Mr. Young is a Managing Director of Longitude Capital. Prior to joining Longitude Capital in 2022, Mr. Young was the Chief Operating Officer and Chief Financial Officer of GRAIL, a developer of blood cancer tests that was acquired by Illumina (ILMN) for $8 billion in 2021. From 2013 to 2019, Mr. Young held positions of increasing responsibility at Jazz Pharmaceuticals (JAZZ), a Longitude portfolio company, most recently as Executive Vice President and Chief Financial Officer. Prior to Jazz, Mr. Young was an investment banker for nearly 20 years at Barclays Capital, Citigroup, Lehman Brothers, and Merrill Lynch, where he advised and led financings for hundreds of emerging and established life science companies. Additionally, Mr. Young served on the board of PRA Health Sciences (PRAH) until its acquisition by ICON plc for $12 billion in 2021, and currently serves as Lead Independent Director and Chairman of the Audit Committee of CytomX Therapeutics (CTMX) as well as a board member of Alpha-9 Oncology, Avenge Bio, and OrsoBio. Mr. Young holds an MBA and a BS in Economics from the Wharton School of the University of Pennsylvania.

Gans Ganapati

Co-Founder and Chief Business and Financial Officer

Gans Ganapati, Co-Founder and Chief Business and Financial Officer of OrsoBio, brings over 25 years of business leadership experience. He was VP of Corporate Development and a member of the founding management team of Adamas Pharmaceuticals (Nasdaq: ADMS), where he was closely associated with the early development of Gocovri® and the outlicensing of Namzaric® to Forest Laboratories. Previously, he was a co-founder of HealthCare Global Enterprises (NSE:HCG), the largest provider of cancer care in India where he steered the company through multiple financings and IPO. He also served as founder and CEO of Triesta Sciences, an oncology CRO. Gans began his career in the M&A department of Credit Suisse First Boston in New York and Palo Alto. He received an MBA from the Wharton School of the University of Pennsylvania and is a graduate of the Indian Institute of Technology, Madras.

Recent News

OrsoBio team members collaborated with Professor Takebe in his pioneering study in Cell on the first use of en masse human liver organoids to define the genetic basis of metabolic liver disease and potential for tailored therapeutic development.